Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica.
To evaluate the incidence and risks of adverse events associated with therapy (both corticosteroids [CS] and nonsteroidal antiinflammatory drugs [NSAIDs]) among a previously identified, population-based cohort of patients first diagnosed with polymyalgia rheumatica (PMR) between 1970 and 1991 who were followed up over the long term.
Information on demographics, PMR diagnosis, disease course, and drug therapy, in addition to data on adverse events commonly associated with CS and NSAID treatment, was obtained from the Rochester Epidemiology Project database.
Cox proportional hazards and regression analysis models were used to evaluate the relationship between the occurrence of these events and therapy.
Of the 232 patients (69 male, 163 female) included in the study, the mean age at PMR diagnosis was 72.9 years, the average followup was 8.0 years, and 30 patients were also diagnosed with giant cell (temporal) arteritis.
Among the 175 patients (49 male, 126 female) treated with CS, the mean duration of CS therapy was 2.4 years, the average daily dose was 9.6 mg, and the mean cumulative dose was 8.4 gm.
In total, 65% of the 124 patients treated with CS alone experienced at least 1 adverse event, compared with 67% of the 57 patients treated with NSAIDs alone and 80% of the 51 patients treated with CS and NSAIDs.
The average time from initiation of therapy to the first adverse event was 1.6 years (n=160). (...)
Mots-clés Pascal : Pseudopolyarthrite rhizomélique, Traitement, Chimiothérapie, Antiinflammatoire non stéroïde, Corticostéroïde, Toxicité, Epidémiologie, Facteur risque, Incidence, Long terme, Homme, Chronique, Système ostéoarticulaire pathologie, Rhumatisme inflammatoire
Mots-clés Pascal anglais : Polymyalgia rheumatica, Treatment, Chemotherapy, Non steroidal antiinflammatory agent, Corticosteroid, Toxicity, Epidemiology, Risk factor, Incidence, Long term, Human, Chronic, Diseases of the osteoarticular system, Inflammatory joint disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0529661
Code Inist : 002B02U10. Création : 13/02/1998.